FUNDAMENTALS · Fundamentals · US Healthcare

Integra LifeSciences Holdings (IART) Fundamentals 2026 — Revenue Analysis | SniperIQ

Integra LifeSciences Holdings (IART) is a US-listed Healthcare company in Medical - Devices with a market capitalization of

.5B, trading at
8.70 on the NASDAQ. This SniperIQ fundamentals page covers Integra LifeSciences Holdings's valuation, profitability (net margin -30.1%), revenue (
.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
.5B
Net Margin-30.1%
Revenue (FY25)
.6B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Integra LifeSciences Holdings's market cap?

Integra LifeSciences Holdings (IART) has a market capitalization of approximately

.5B, trading at
8.70 on the NASDAQ. Market cap moves with the live share price.

What is Integra LifeSciences Holdings's P/E ratio?

Integra LifeSciences Holdings's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Integra LifeSciences Holdings?

Integra LifeSciences Holdings runs a net profit margin of -30.1%, a gross margin of 53.2%, and an operating margin of 7.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Integra LifeSciences Holdings generate?

Integra LifeSciences Holdings reported revenue of

.6B for fiscal year 2025, with net income of -$516M and earnings per share (EPS) of -6.73. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Integra LifeSciences Holdings pay a dividend?

Integra LifeSciences Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Integra LifeSciences Holdings financially healthy?

Integra LifeSciences Holdings carries a debt-to-equity ratio of 1.96x and a current ratio of 3.38x, with a market beta of 1.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Integra LifeSciences Holdings a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Integra LifeSciences Holdings (IART) the key facts are: market cap

.5B, revenue
.6B, 52-week range 8.7-20.26. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Integra LifeSciences Holdings's full fundamentals live

Get Integra LifeSciences Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Xeris Biopharma Holdings (XERS) fundamentals · Zhaoke Ophthalmology (6622) fundamentals · Perrigo (PRGO) fundamentals · ImmuneOnco Biopharmaceuticals (Shanghai) (1541) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons